Psychometric properties of the Chinese version of the Reproductive Concerns After Cancer Scale (RCAC) for young female cancer survivors.
This study aimed to translate, culturally adapt, and test the psychometric properties of the Reproductive Concerns After Cancer scale (RCAC) in young Chinese female cancer survivors. The Chinese version of the RCAC was developed using the standard Functional Assessment of Chronic Illness Therapy (FACIT) translation methodology, and then 800 young Chinese female cancer survivors were recruited to complete the scale. The validation of the RCAC is as follows: (1) content validity was evaluated by a group of experts; (2) factor structure was assessed using confirmatory factor analysis and factorial invariance analysis; (3) convergent validity was determined by correlations with the Patient Health Questionnaire 9 (PHQ-9) and Functional Assessment of Cancer Therapy-General (FACT-G) scale; (4) internal consistency reliability was assessed using Cronbach's α coefficient; and (5) test-retest reliability was assessed using intra-class correlations. Internal consistency (Cronbach's alpha coefficients ranged from 0.71 to 0.81) and test-retest reliability (intra-class correlation coefficients ranged from 0.82 to 0.95) of the Chinese version of the RCAC were satisfactory. Results also indicated that the content validity index of the RCAC (Chinese version) was good. The Chinese version of the RCAC score was correlated with the PHQ-9 (r = 0.568, p < 0.01) and FACT-G (r = -0.524, p < 0.01) scores, which indicated acceptable convergent validity. Confirmatory factor analysis supported a six-factor structure of the Chinese version of the RCAC with a good model fit. Moreover, multi-group confirmatory factor analysis indicated factorial invariance (configural, metric, scalar, and strict invariance) of the RCAC across cancer types. The translation and cross-cultural adaption of the RCAC into Chinese was successful. The Chinese version of the RCAC has suitable factor structure and psychometric properties for reproductive concerns evaluation in young female cancer patients and is appropriate to use in clinical trials of Chinese patients.